Transformation of quercitols into 4-methylenecyclohex-5-ene-1,2,3-triol derivatives, precursors for the chemical chaperones N-octyl-4-epi-β- valienamine (NOEV) and N-octyl-β-valienamine (NOV)

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 23, 2011, Pages 7189-7192

  Kuno, Shinichi ^a   Takahashi, Atsushi ^a   Ogawa, Seiichiro ^b  

^a Hokko Chemical Industry Co Ltd ^*  (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Carbasugar; Carbohydrate mimics; Chemical chaperone; Glycosidase inhibitors; Quercitol; Structure activity relationship; Valienamine

Indexed keywords

4 METHYLENECYCLOHEX 5 ENE 1,2,3 TRIOL DERIVATIVE; GLYCOSIDASE INHIBITOR; N OCTYL 4 EPI BETA VALIENAMINE; N OCTYL BETA VALIENAMINE; QUERCITOL; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; ENZYME INHIBITION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANILINE COMPOUNDS; ANIMALS; CARBOHYDRATE SEQUENCE; CATTLE; CYCLOHEXANES; ECDYSONE; ENZYME INHIBITORS; HEXOSAMINES; INHIBITORY CONCENTRATION 50; INOSITOL; LIVER; METHYLENE CHLORIDE; MOLECULAR SEQUENCE DATA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80255138767     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.09.067     Document Type: Article

References (34)

1. S. Ogawa, S. Uetsuki, Y. Tezuka, T. Morikawa, A. Takahashi, and K. Sato Bioorg. Med. Chem. Lett. 9 1999 1493
2. A. Takahashi, K. Kanbe, T. Tamamura, and K. Sato Anticancer Res. 1999 3807
3. For relevant reports, see: S. Ogawa, H. Aoyama, and Y. Tezuka J. Carbohydr. Chem. 20 2001 703
4. S. Ogawa, Y. Ohishi, M. Asada, A. Tomoda, A. Takahashi, Y. Ooki, M. Mori, M. Itoh, and T. Korenaga Org. Biomol. Chem. 2 2004 884
5. S. Ogawa, M. Asada, Y. Ooki, M. Mori, M. Itoh, and T. Korenaga Bioorg. Med. Chem. 13 2005 4306
6. S. Ogawa, and Y. Tezuka Bioorg. Med. Chem. Lett. 16 2006 5238
7. S. Ogawa, and M. Kanto J. Nat. Prod. 70 2007 493
8. S. Wacharasindhu, W. Worawalai, W. Rungprom, and P. Phuwapraisirisan Tetrahedron Lett. 50 2009 2189
9. For recent references concerning synthetic approaches to valienamine derivatives: Y.-K. Chang, B.-Y. Lee, D.J. Kim, G.S. Lee, H.B. Jeon, and K.S. Kim J. Org. Chem. 70 2005 3299
10. I. Cumpstey Tetrahedron Lett. 46 2005 6257
11. R. Lysek, C. Schuetz, S. Favre, A.C. O'Sullivan, C. Pillonel, T. Kruelle, P.M.J. Jung, I. Clotet-Codina, J.A. Este, and P. Vogel Bioorg. Med. Chem. 14 2006 6255
12. A. Scaffidi, K.A. Stubbs, R.J. Dennis, E.J. Taylor, G.J. Davies, D.J. Vocadlo, and R.V. Stick Org. Biomol. Chem. 5 2007 3013
13. I. Cumpstey, S. Gehrke, S. Erfan, and R. Cribiu Carbohydr. Res. 343 2008 1675
14. P.R. Krishna, and P.S. Reddy Synlett 2 2009 209
15. C. Ramstadius, O. Hekmat, L. Eriksson, H. Stalbrand, and I. Cumpstey Tetrahedron: Asymmetry 20 2009 795
16. Y.-K. Chang, H.-J. Lo, and T.-H. Yan Org. Lett. 11 2009 4278
17. T.K.M. Shing, and H.M. Cheng J. Org. Chem. 75 2010 3522
18. Y. Suzuki, S. Ogawa, and Y. Sakakibara Perspect. Med. Chem. 3 2009 7
19. S. Ogawa, Y. Iwasawa, T. Nose, T. Suami, S. Ohba, M. Ito, and Y. Saito J. Chem. Soc., Perkin Trans. 1 1985 903
20. For relevant reports, see: S. Ogawa, M. Ashiura, C. Uchida, S. Watanabe, C. Yamazaki, K. Yamagishi, and J. Inokuchi Bioorg. Med. Chem. Lett. 6 1996 929
21. S. Ogawa, Y.K. Matsunaga, and Y. Suzuki Bioorg. Med. Chem. 10 2002 1967
22. J. Matsuda, O. Suzuki, A. Oshima, Y. Yamamoto, A. Noguchi, K. Takimoto, M. Itoh, Y. Matsuzaki, Y. Yasuda, S. Ogawa, Y. Sakata, E. Nanba, K. Higaki, Y. Ogawa, L. Tominaga, K. Ohno, H. Iwasaki, H. Watanabe, R.O. Brady, and Y. Suzuki Proc. Natl. Acad. Sci. U.S.A. 100 2003 15912
23. H. Lin, Y. Sugimoto, Y. Ohsaki, H. Ninomiya, A. Oka, M. Taniguchi, H. Ida, Y. Eto, S. Ogawa, Y. Matsuzaki, M. Sawa, T. Inoue, K. Higaki, E. Nanba, K. Ohno, and Y. Suzuki Biochim. Biophys. Acta Mol. Basis Dis. 1689 2004 219
24. S. Ogawa, Y. Sakata, N. Ito, M. Watanabe, K. Kabayama, M. Itoh, and T. Korenaga Bioorg. Med. Chem. 12 2004 995
25. K. Lei, H. Ninomiya, M. Suzuki, T. Inoue, M. Sawa, M. Iida, H. Ida, Y. Eto, S. Ogawa, K. Ohno, and Y. Suzuki Biochim. Biophys. Acta Mol. Basis Dis. 1772 2007 587
26. Y. Suzuki Cell. Mol. Life Sci. 65 2008 351
27. Z. Luan, H. Ninomiya, K. Ohno, S. Ogawa, T. Kubo, M. Iida, and Y. Suzuki Brain Dev. 32 2010 805
28. Z. Luan, L. Li, H. Ninomiya, K. Ohno, S. Ogawa, T. Kubo, M. Iida, and Y. Suzuki Blood Cells Mol. Dis. 44 2010 48
29. H. Jo, K. Yugi, S. Ogawa, Y. Suzuki, and Y. Sakakibara J. Proteomics Bioinform. 3 2010 104
30. Nysted, L. N. U.S. Patent 3,865,848, 1975. This reagent was purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).
31. S. Matsubara, M. Sugihara, and K. Utimoto Synlett 1998 313
32. 1H NMR data corresponds well to that of racemic 12 (Ogawa, S.; Toyokuni, T.; Omata, M.; Chida, N.; Suami, T. Bull. Chem. Soc. Jpn. 1980, 53, 455).
33. The formation of the single β-amine through direct amination of α- and β-bromo compounds was mechanistically explained by presuming a neighboring group participation (Ref. 6e, and also see: Toyokuni, T.; Ogawa, S.; Suami, T. Bull. Chem. Soc. Jpn. 1983, 56, 2999)
34. In contrast, without neighboring group participation, the amination of the relevant bromo compounds resulted in the generation of the nonstereospecific products (Cumpstey, I.; Ramstadius, C.; Borbas, K. E. Synlett, 2011, 12, 1701).